.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
Merck
Argus Health
McKesson
Federal Trade Commission
Express Scripts
Julphar
US Department of Justice
Harvard Business School

Generated: December 12, 2017

DrugPatentWatch Database Preview

INVANZ Drug Profile

« Back to Dashboard

Which patents cover Invanz, and when can generic versions of Invanz launch?

Invanz is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-two patent family members in forty countries and seven supplementary protection certificates in five countries.

The generic ingredient in INVANZ is ertapenem sodium. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ertapenem sodium profile page.
Drug patent expirations by year for INVANZ

Pharmacology for INVANZ

Ingredient-typeCarbapenems
Drug ClassPenem Antibacterial

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Merck Sharp DohmeINVANZertapenem sodiumINJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 2001RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INVANZ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp DohmeINVANZertapenem sodiumINJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 2001► Subscribe► Subscribe
Merck Sharp DohmeINVANZertapenem sodiumINJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 2001► Subscribe► Subscribe
Merck Sharp DohmeINVANZertapenem sodiumINJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 2001► Subscribe► Subscribe
Merck Sharp DohmeINVANZertapenem sodiumINJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for INVANZ

Drugname Dosage Strength RLD Submissiondate
ertapenemInjection1 g/vialInvanz6/20/2013

International Patent Family for Tradename: INVANZ

Country Document Number Estimated Expiration
Serbia49583► Subscribe
Mexico9800808► Subscribe
Poland188917► Subscribe
Brazil9702231► Subscribe
Turkey9800146► Subscribe
Canada2227994► Subscribe
Estonia04678► Subscribe
Bulgaria63821► Subscribe
Japan5255983► Subscribe
Poland324746► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INVANZ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0863901/01Switzerland► SubscribeFORMER OWNER: SCHERING CORPORATION, US
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
00104Netherlands► SubscribePRODUCT NAME: ERTAPENEM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ERTAPENEMNATRIUM; NAT. REGISTRATION NO/DATE: EU/1/02/216/001 20020418; FIRST REGISTRATION: EU/1/02/216/001 20020418
0579826/01Switzerland► SubscribePRODUCT NAME: ERTAPENEM; REGISTRATION NUMBER/DATE: SWISSMEDIC 55902 02.12.2005
2004008,C0863901Lithuania► SubscribePRODUCT NAME: ERTAPENEMUM ((4R,5S,6S)-3-((3S,5S)-5-((3-KARBOKSIFENIL)AMINO)KARBONIL)-3-PIROLIDINIL)TIO)-6-((1R)-1HIDROKSIETIL)-4-METIL-7-OKSO-1-AZABICIKLO-(3.2.0)HEPT-2-EN-2-KARBOKSIRUGSTIS; REGISTRATION NO/DATE: 03/8043/3 20030328
C0041France► SubscribePRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
2004008Lithuania► SubscribePRODUCT NAME: ERTAPENEMUM ([4R,5S,6S]-3-[(3S,5S)-5-[(3-KARBOKSIFENIL) AMINO]KARBONIL]-3-PIROLIDINIL]TIO]-6-[(1R)-1HIDROKSIETIL]-4-METIL-7-OKSO-1-AZABICIKLO-[3.2.0]HEPT-2-EN-2-KARBOKSIRUGSTIS; REGISTRATION NO/DATE: 03/8043/3 20030328
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
Daiichi Sankyo
Merck
Queensland Health
Cantor Fitzgerald
Baxter
UBS
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot